HomePress-release

Redding, California - June 14, 2024

Viral Vaccines Market to be Worth $47.01 Billion by 2031

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated) Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging - Global Forecast to 2031

Meticulous Research^®—a leading market research company, published a research report titled, ‘Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated) Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging—Global Forecast to 2031’

According to this latest publication from Meticulous Research^®, the viral vaccines market is projected to reach $47.01 billion by 2031, at a CAGR of 1.9% from 2024 to 2031. The growth of the viral vaccines market is driven by the strong product pipeline for vaccines, increasing government focus on immunization programs, technological advancements in vaccine administration, use of inactivated vaccines in surgeries or treatment, and the capacity expansion of biopharmaceutical products. Moreover, the growing focus on therapeutic vaccines, increasing use of adjuvants in vaccines, growth prospects in emerging markets, and development of highly stable and energy-efficient ultra-low temperature freezers are expected to offer growth opportunities for the players operating in this market.

Key Players

The key players profiled in the viral vaccines market report are Pfizer, Inc. (U.S.), AstraZeneca plc (U.K.), GlaxoSmithKline plc (U.K.), Sanofi S.A. (Italy), CSL Ltd. (Australia), Mitsubishi Tanabe Pharma Corporation (Japan), Merck & Co., Inc. (U.S.), Moderna, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Dynavax Technologies Corporation (U.S.), Serum Institute of India Pvt. Ltd (India), Emergent BioSolutions, Inc. (U.S.), Bharat Biotech International Limited (BBIL) (India), and Valneva SE (France).

The viral vaccines market is segmented by Form (Liquid Vaccines, Lyophilized Vaccines), Vaccine Type (Live-attenuated Vaccines, Inactivated Vaccines, mRNA Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines), Virus Type (Adenovirus, Retrovirus, Plasmid DNA, Adeno-associated Virus (AAV), Lentivirus, and Other Virus Types), Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, and Other Routes of Administration), Approach (Preventive Vaccines, Therapeutic Vaccines), Indication (Infectious Diseases, Cancer, Genetic Disorders, and Other Indications), Application (Antisense Therapy, Gene Therapy, Cell Therapy, and Vaccinology), Packaging (Vials, Prefilled Syringes) and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.

Among all forms studied in the report, in 2024, the liquid vaccines segment is expected to account for the largest share of the market. Liquid vaccines contain formulations in the liquid form which are easy to administer. The large market share of the segment is attributed to factors such as ease of administration, no reconstitution of vaccines needed, reduced risk of errors, simplified logistics as compared to lyophilized vaccines, decreased need for equipment and training requirements, lower contamination risks, growing prevalence of infectious diseases, and reduced wastage of vaccine accessories.

Among all vaccine types studied in the report, in 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the absence of live components or microorganisms, precise targeting of pathogens, capability of eliciting a protective immune response, low risk of immunogenicity, and long-term immunity.

Among all virus types studied in the report, in 2024, the adenovirus segment is expected to account for the largest share of the market. The large share of this segment is attributed to efficient gene delivery, strong immune response, replication-incompetent viruses, and high scalability as compared to other virus types. Institutes, organizations, and companies have been collaborating to increase the number of immunizations for various infectious diseases. For instance, in January 2024, ReiThera Srl (Italy), the Ragon Institute of Mass General, MIT, and Harvard (U.S.), and the International AIDS Vaccine Initiative, Inc. (IAVI) (U.S.) announced a collaboration to develop a novel HIV vaccine candidate that comprises ReiThera’s GRAd vector and HIV T-cell epitopes. These organizations will perform vector engineering and generation, process development, good manufacturing practice (GMP), and preclinical development to evaluate the safety and immunogenicity of the GRAd-HIV vaccine for clinical use.

Among all approaches studied in the report, in 2024, the preventive vaccines segment is expected to account for the larger share of the market. Preventive vaccines are provided to people with the goal of not contracting infections due to viruses or bacteria. The large market share of this segment is attributed to the increasing prevalence of chronic and infectious diseases, rising awareness for immunization in public, growing immunization programs, induction of herd immunity, and the prevention of disease outbreaks.

Among all indications studied in the report, the infectious diseases segment is expected to account for the largest share of the market. The large growth of the segment is attributed to factors such as prevention of diseases, reduced morbidity and mortality rates, cost-effectiveness, global health security, increased herd immunity, long-term protection, and the increasing prevalence of infectious diseases. According to the World Health Organization (WHO), approximately 1.5 million children under the age of 5 lose their lives due to vaccine-preventable diseases every year. Various companies are manufacturing vaccines and therapeutics to reduce the number of fatalities due to infectious diseases. For instance, in October 2023, the R21/Matrix-M malarial vaccines developed by Oxford University (U.K.) and the Serum Institute of India Pvt Ltd. (India), using Novartis AG’s (Switzerland) adjuvant technology, was recommended by the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG)

Among all applications studied in the report, in 2024, the antisense therapy segment is expected to account for the largest share of the market. The large market share of this segment is attributed to factors such as the growing prevalence of infectious diseases, technological advancements in the use of viral vectors, and increasing healthcare expenditure. Antisense vaccines are capable of inducing both humoral (antibody-mediated) and cellular immune responses. This comprehensive immune response can protect against a wide range of pathogens and enhance vaccine efficacy, supporting their largest adoption.

Among all geographies, in 2024, North America is expected to account for the largest share of the market. The large share of this regional market is attributed to factors such as advanced research infrastructure in the region, the presence of key pharmaceutical companies, collaborations between research institutes and pharmaceutical companies, the establishment of new facilities in the region by key players, awareness for vaccination, and risk of emerging pandemics.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920

Key questions answered in the report:

Which are the high-growth market segments in terms of viral vaccines by form, vaccine type, virus type, route of administration, approach, indication, application, and geography?
What was the historical market for viral vaccines across the globe?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, opportunities, and challenges in the viral vaccines market?
Who are the major players operating in the viral vaccines market?
What is the competitive landscape, and who are the leaders in the viral vaccines market?
What are the recent developments in the viral vaccines market?
What are the different strategies adopted by the major players in the viral vaccines market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researc

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - June 14, 2024

Viral Vaccines Market to be Worth $47.01 Billion by 2031

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated) Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies